Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibudilast in Methamphetamine Dependence
NCT03341078Phase 2Completed
- Sponsor
- VA Office of Research & Development
- Start
- May 2019
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ibudilast in methamphetamine use disorder (MUD) (3 arms), sponsored by VA Office of Research & Development. Primary endpoint: Effects of ibudilast on brain function as assessed by magnetic resonance imaging (MRI) at 6 weeks. Started May 2019; status: completed.
02
Drugs
ibudilast
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT03341078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341078.